Zobrazeno 1 - 10
of 40
pro vyhledávání: ''
Autor:
Ali Al-Zahrani, Taher Al-Tweigeri, Osama Al Malik, Asma Tulbah, Adher Al-Sayed, Said Dermime, Mohamed Alshabanah, Adnan Ezzat, Naser Elkum, Dahish Ajarim
Publikováno v:
BASE-Bielefeld Academic Search Engine
BMC Cancer
BMC Cancer, Vol 7, Iss 1, p 222 (2007)
BMC Cancer
BMC Cancer, Vol 7, Iss 1, p 222 (2007)
Background Breast cancer in young Saudi women is a crucial problem. According to the 2002 annual report of Saudi National Cancer Registry, breast cancers that developed before the age of 40 comprise 26.4% of all female breast cancers comparing to 6.5
Autor:
Yalai Bai, William M. Sikov, David L. Rimm, Maysa M. Abu-Khalaf, Lyndsay Harris, Veerle Bossuyt, Huan Cheng, Natalie Sinclair
Publikováno v:
BMC Cancer
Background Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive (HER2+) breast cancers but traditional methods of measuring HER2 expression
Autor:
Yoko Nakasu, Koichi Mitsuya, Nakamasa Hayashi, Junichiro Watanabe, Hideyuki Harada, Ichiro Ito
Publikováno v:
BMC Cancer
Background Multiple new targeted agents have been developed for patients with human epidermal growth factor receptor type 2 (HER2) – positive breast cancer. Patients with HER2– positive breast cancer will develop brain metastases with greater inc
Autor:
Jin Seok Ahn, Yoon-La Choi, Hyun Jung Jun, Yeon Hee Park, Myung Hee Chang, Eun Yoon Cho, Min Jae Park, Young-Hyuck Im, Ji Eun Uhm, Do Hyoung Lim, Sang Hoon Ji, Kyoung Ha Kim, Seong Yoon Yi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
Background We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype. Methods A retrospective analysis
Publikováno v:
BMC Cancer
Background Dermatomyositis is an autoimmune myopathy characterized by proximal muscle weakness, muscle inflammation, and typical skin findings. It is a rare disease with an incidence of ~1/100 000. About 15–30 % of adult-onset cases are caused by u
Autor:
Yvonne Nestoriuc, Franziska Schuricht, Ute-Susann Albert, Winfried Rief, Pia von Blanckenburg
Publikováno v:
BMC Cancer
Background Adjuvant endocrine therapy can improve disease-free survival and time before recurrence in breast cancer patients. However, it is associated with considerable side effects that negatively affect patients’ quality of life and cause non-ad
Publikováno v:
BMC Cancer, Vol 10, Iss 1, p 228 (2010)
BMC Cancer
BMC Cancer
Background The 2007 St Gallen international expert consensus statement describes three risk categories and provides recommendations for treatment of early breast cancer. The set of recommendations on how to best treat primary breast cancer is recogni
Autor:
Gina Bouchard, Yves Bérubé-Lauzière, Hélène Therriault, Sameh Geha, Rachel Bujold, Caroline Saucier, Benoit Paquette
Publikováno v:
BMC Cancer
Background Some triple negative breast cancer (TNBC) patients are at higher risk of recurrence in the first three years after treatment. This rapid relapse has been suggested to be associated with inflammatory mediators induced by radiation in health
Autor:
Karin Jirström, Donal J. Brennan, William M. Gallagher, Elton Rexhepaj, Michael J. Duffy, Darran P. O'Connor, Sallyann L. O'Brien, Göran Landberg
Publikováno v:
BMC Cancer
BMC Cancer; 10 (2010)
BMC Cancer, Vol 10, Iss 1, p 639 (2010)
BMC Cancer; 10 (2010)
BMC Cancer, Vol 10, Iss 1, p 639 (2010)
Background Conflicting data exist regarding the prognostic and predictive impact of survivin (BIRC5) in breast cancer. We previously reported survivin cytoplasmic-to-nuclear ratio (CNR) as an independent prognostic indicator in breast cancer. Here, w
Autor:
Taijiro Kosaka, Masahiko Tanabe, Atsushi Arakawa, Hiroshi Sonoue, Fumie Igari, Hideo Shimizu, Koji Senuma, Emi Tokuda, Yoshiya Horimoto, Mitsue Saito
Publikováno v:
BMC Cancer
Background Patients with luminal HER2-negative tumours have a favourable prognosis. However, there is a subpopulation in which poorer outcomes are obtained with endocrine therapy alone. This subpopulation is considered to benefit from chemotherapy. H